News on research and diagnostic developments in neuroscience.
A diagnostic test could be available within about a year that researchers and clinicians could use to diagnose patients and develop therapies.
The companies will develop a smartphone-based platform to offer molecular tests enabling the precision treatment of psychiatric disorders.
Assurex Health will use the MassArray system with its GeneSight Psychotropic pharmacogenetic test.
The partners have formed a public/private partnership to foster collaboration and data integration between different institutes researching brain trauma.
The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.